{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:05:24Z","timestamp":1759813524103},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s00482-012-1214-9","type":"journal-article","created":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T16:51:35Z","timestamp":1346950295000},"page":"550-567","source":"Crossref","is-referenced-by-count":6,"title":["Glukokortikoide und Androgene zur Behandlung von M\u00fcdigkeit und Schw\u00e4che bei Palliativpatienten"],"prefix":"10.1007","volume":"26","author":[{"given":"A.","family":"Thiem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rolke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Radbruch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,14]]},"reference":[{"key":"1214_CR1","first-page":"1877","volume":"53","author":"NIH","year":"1996","unstructured":"NIH (1996) NIH releases statement on behavioral and relaxation approaches for chronic pain and insomnia. Am Fam Physician 53:1877\u20131878, 1880","journal-title":"Am Fam Physician"},{"key":"1214_CR2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00435383","volume":"3","author":"Portenoy","year":"1994","unstructured":"Portenoy RK et al (1994) Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 3:183\u2013189","journal-title":"Qual Life Res"},{"key":"1214_CR3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1525-1438.2002.t01-1-01147.x","volume":"12","author":"Barnes","year":"2002","unstructured":"Barnes EA, Bruera E (2002) Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer 12:424\u2013428","journal-title":"Int J Gynecol Cancer"},{"key":"1214_CR4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/0269216307085183","volume":"22","author":"Radbruch","year":"2008","unstructured":"Radbruch L et al (2008) Fatigue in palliative care patients \u2013 an EAPC approach. Palliat Med 22:13\u201332","journal-title":"Palliat Med"},{"key":"1214_CR5","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jpainsymman.2009.05.013","volume":"38","author":"Lee","year":"2009","unstructured":"Lee KA et al (2009) Symptom experience in HIV-infected adults: a function of demographic and clinical characteristics. J Pain Symptom Manage 38:882\u2013893","journal-title":"J Pain Symptom Manage"},{"key":"1214_CR6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1191\/135248506ms1262oa","volume":"12","author":"Minden","year":"2006","unstructured":"Minden SL et al (2006) The sonya slifka longitudinal multiple sclerosis study: methods and sample characteristics. Mult Scler 12:24\u201338","journal-title":"Mult Scler"},{"key":"1214_CR7","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/jnnp.2008.163246","volume":"80","author":"McElhiney","year":"2009","unstructured":"McElhiney MC, Rabkin JG, Gordon PH et al (2009) Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry 80:1146\u20131149","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1214_CR8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1751-7133.2010.00203.x","volume":"17","author":"Quevedo","year":"2011","unstructured":"Quevedo HC, Deravil D, Seo DM, Hebert KA (2011) The meaningful use of the review of symptoms in heart failure patients. Congest Heart Fail 17:31\u201337","journal-title":"Congest Heart Fail"},{"key":"1214_CR9","unstructured":"Peters JB et al (2010) Course of normal and abnormal fatigue in patients with chronic obstructive pulmonary disease, and its relationship with domains of health status. Patient Educ Couns"},{"key":"1214_CR10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"Fearon","year":"2011","unstructured":"Fearon K et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489\u2013495","journal-title":"Lancet Oncol"},{"key":"1214_CR11","unstructured":"Herold G (2011) Innere Medizin. Herold, K\u00f6ln"},{"key":"1214_CR12","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/314027","volume":"31","author":"Wanke","year":"2000","unstructured":"Wanke CA et al (2000) Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 31:803\u2013805","journal-title":"Clin Infect Dis"},{"key":"1214_CR13","doi-asserted-by":"crossref","unstructured":"Yennurajalingam S, Bruera E (2010) Fatigue and asthenia. In: Hanks G et al (Hrsg) Oxford textbook of palliative medicine. Oxford University Press, Oxford","DOI":"10.1093\/med\/9780198570295.003.0073"},{"key":"1214_CR14","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/cncr.20028","volume":"100","author":"Rajagopal","year":"2004","unstructured":"Rajagopal A, Vassilopoulou-Sellin R, Palmer JL et al (2004) Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 100:851\u2013858","journal-title":"Cancer"},{"key":"1214_CR15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1470-2045(10)70021-8","volume":"11","author":"Vigano","year":"2010","unstructured":"Vigano A et al (2010) Male hypogonadism associated with advanced cancer: a systematic review. Lancet Oncol 11:679\u2013684","journal-title":"Lancet Oncol"},{"key":"1214_CR16","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1002\/cncr.21889","volume":"106","author":"Garcia","year":"2006","unstructured":"Garcia JM et al (2006) Hypogonadism in male patients with cancer. Cancer 106:2583\u20132591","journal-title":"Cancer"},{"key":"1214_CR17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1477-7827-9-26","volume":"9","author":"Aloisi","year":"2011","unstructured":"Aloisi AM et al (2011) Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients. Reprod Biol Endocrinol 9:26","journal-title":"Reprod Biol Endocrinol"},{"key":"1214_CR18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1191\/0269216304pm852oa","volume":"18","author":"Nauck","year":"2004","unstructured":"Nauck F et al (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18:100\u2013107","journal-title":"Palliat Med"},{"key":"1214_CR19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/026921639400800207","volume":"8","author":"Twycross","year":"1994","unstructured":"Twycross RG, Bergl S, John S, Lewis K (1994) Monitoring drug use in palliative care. Palliat Med 8:137\u2013143","journal-title":"Palliat Med"},{"key":"1214_CR20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s005200000218","volume":"9","author":"Mercadante","year":"2001","unstructured":"Mercadante S, Fulfaro F, Casuccio A (2001) The use of Kortikosteroids in home palliative care. Support Care Cancer 9:386\u2013389","journal-title":"Support Care Cancer"},{"key":"1214_CR21","first-page":"261","volume":"35","author":"Good","year":"2006","unstructured":"Good PD et al (2006) What are the essential medications in pallative care? \u2013 A survey of Australian palliative care doctors. Aust Fam Physician 35:261\u2013264","journal-title":"Aust Fam Physician"},{"key":"1214_CR22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/J354v21n04_14","volume":"21","author":"Shih","year":"2007","unstructured":"Shih A, Jackson KC II (2007) Role of Kortikosteroids in palliative care. J Pain Palliat Care Pharmacother 21:69\u201376","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"1214_CR23","doi-asserted-by":"crossref","first-page":"406","DOI":"10.12968\/ijpn.2010.16.8.406","volume":"16","author":"Mumford","year":"2010","unstructured":"Mumford S (2010) Reviewing the evidence for prescribing steroids for non-specific symptoms in patients with advanced cancer. Int J Palliat Nurs 16:406\u2013410","journal-title":"Int J Palliat Nurs"},{"key":"1214_CR24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1634\/theoncologist.12-S1-43","volume":"12","author":"Carroll","year":"2007","unstructured":"Carroll JK, Kohli S, Mustian KM et al (2007) Pharmacologic treatment of cancer-related fatigue. Oncologist 12(Suppl 1):43\u201351","journal-title":"Oncologist"},{"key":"1214_CR25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.297.3.295","volume":"297","author":"Yennurajalingam","year":"2007","unstructured":"Yennurajalingam S, Bruera E (2007) Palliative management of fatigue at the close of life: \u201eit feels like my body is just worn out\u201c. JAMA 297:295\u2013304","journal-title":"JAMA"},{"key":"1214_CR26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1188\/08.CJON.S2.27-36","volume":"12","author":"Breitbart","year":"2008","unstructured":"Breitbart W, Alici Y (2008) Pharmacologic treatment options for cancer-related fatigue: current state of clinical research. Clin J Oncol Nurs 12:27\u201336","journal-title":"Clin J Oncol Nurs"},{"key":"1214_CR27","doi-asserted-by":"crossref","unstructured":"Johns K, Beddall MJ, Corrin RC (2005) Anabolic steroids for the treatment of weight loss in HIV-infected individuals. Cochrane Database Syst Rev CD005483","DOI":"10.1002\/14651858.CD002836.pub2"},{"key":"1214_CR28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/13543784.2011.544651","volume":"20","author":"Woerdeman","year":"2011","unstructured":"Woerdeman J, Ronde W de (2011) Therapeutic effects of anabolic androgenic steroids on chronic diseases associated with muscle wasting. Expert Opin Investig Drugs 20:87\u201397","journal-title":"Expert Opin Investig Drugs"},{"key":"1214_CR29","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1210\/jc.86.11.5108","volume":"86","author":"Basaria","year":"2001","unstructured":"Basaria S, Wahlstrom JT, Dobs AS (2001) Clinical review 138: anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab 86:5108\u20135117","journal-title":"J Clin Endocrinol Metab"},{"key":"1214_CR30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ncpendmet0120","volume":"2","author":"Bhasin","year":"2006","unstructured":"Bhasin S et al (2006) Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2:146\u2013159","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"1214_CR31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000176052","volume":"37","author":"Bhasin","year":"2009","unstructured":"Bhasin S, Storer TW (2009) Anabolic applications of androgens for functional limitations associated with aging and chronic illness. Front Horm Res 37:163\u2013182","journal-title":"Front Horm Res"},{"key":"1214_CR32","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jpainsymman.2010.06.020","volume":"41","author":"Minton","year":"2011","unstructured":"Minton O, Richardson A, Sharpe M et al (2011) Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage 41:761\u2013767","journal-title":"J Pain Symptom Manage"},{"key":"1214_CR33","first-page":"CD006788","volume":"11","author":"Peuckmann","year":"2010","unstructured":"Peuckmann V, Elsner F, Krumm N et al (2010) Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 11:CD006788","journal-title":"Cochrane Database Syst Rev"},{"key":"1214_CR34","unstructured":"Bausewein C (2005) PCF2, Palliative care formulary, Arzneimitteltherapie in der Palliativmedizin. Elsevier, Urban & Fischer, M\u00fcnchen]"},{"key":"1214_CR35","unstructured":"Aulbert E (2007) Lehrbuch der Palliativmedizin. Schattauer, Stuttgart"},{"key":"1214_CR36","unstructured":"Knipping C (2007) Lehrbuch Palliative Care. Huber, Bern"},{"key":"1214_CR37","doi-asserted-by":"crossref","unstructured":"Zernikow B (2008) Palliativversorgung von Kindern, Jugendlichen und jungen Erwachsenen. Springer, Berlin Heidelberg New York, Heidelberg","DOI":"10.1007\/978-3-540-48876-7"},{"key":"1214_CR38","unstructured":"Bausewein C (2010) Leitfaden Palliative Care \u2013 Palliativmedizin und Hospizbetreuung. Elsevier, M\u00fcnchen"},{"key":"1214_CR39","unstructured":"Hanks G (2010) Oxford textbook of palliative medicine. Oxford University Press, Oxford"},{"key":"1214_CR40","unstructured":"Walsh TD (2009) Palliative medicine. Saunders Elsevier, Philadelphia\/PA"},{"key":"1214_CR41","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"Liberati","year":"2009","unstructured":"Liberati A et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100","journal-title":"PLoS Med"},{"key":"1214_CR42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jpainsymman.2004.01.009","volume":"28","author":"Bruera","year":"2004","unstructured":"Bruera E et al (2004) Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage 28:381\u2013388","journal-title":"J Pain Symptom Manage"},{"key":"1214_CR43","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1200\/JCO.2001.19.1.62","volume":"19","author":"Fossa","year":"2001","unstructured":"Fossa SD et al (2001) Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 19:62\u201371","journal-title":"J Clin Oncol"},{"key":"1214_CR44","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s00520-003-0488-y","volume":"11","author":"Inoue","year":"2003","unstructured":"Inoue A et al (2003) Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer 11:528\u2013532","journal-title":"Support Care Cancer"},{"key":"1214_CR45","first-page":"5602","volume":"54","author":"Lundholm","year":"1994","unstructured":"Lundholm K et al (1994) Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54:5602\u20135606","journal-title":"Cancer Res"},{"key":"1214_CR46","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/0277-5379(89)90353-2","volume":"25","author":"Della","year":"1989","unstructured":"Della Cuna GR, Pellegrini A, Piazzi M (1989) Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 25:1817\u20131821","journal-title":"Eur J Cancer Clin Oncol"},{"key":"1214_CR47","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/0277-5379(89)90354-4","volume":"25","author":"Popiela","year":"1989","unstructured":"Popiela T, Lucchi R, Giongo F (1989) Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 25:1823\u20131829","journal-title":"Eur J Cancer Clin Oncol"},{"key":"1214_CR48","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/1097-0142(197406)33:6<1607::AID-CNCR2820330620>3.0.CO;2-V","volume":"33","author":"Moertel","year":"1974","unstructured":"Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1974) Kortikosteroid therapy of preterminal gastrointestinal cancer. Cancer 33:1607\u20131609","journal-title":"Cancer"},{"key":"1214_CR49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00258123","volume":"14","author":"Schallier","year":"1985","unstructured":"Schallier D, Van Belle S, De Greve J, Willekens A (1985) Methylprednisolone as an antiemetic drug. A randomised double blind study. Cancer Chemother Pharmacol 14:235\u2013237","journal-title":"Cancer Chemother Pharmacol"},{"key":"1214_CR50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/bmj.288.6410.27","volume":"J","author":"Willox","year":"1984","unstructured":"Willox JC et al (1984) Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 288:27","journal-title":"Br Med"},{"key":"1214_CR51","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1200\/JCO.1999.17.10.3299","volume":"17","author":"Loprinzi","year":"1999","unstructured":"Loprinzi CL et al (1999) Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia\/cachexia. J Clin Oncol 17:3299\u20133306","journal-title":"J Clin Oncol"},{"key":"1214_CR52","first-page":"751","volume":"69","author":"Bruera","year":"1985","unstructured":"Bruera E, Roca E, Cedaro L et al (1985) Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69:751\u2013754","journal-title":"Cancer Treat Rep"},{"key":"1214_CR53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1310\/9V0C-YADY-UJNV-T2RT","volume":"4","author":"Hengge","year":"2003","unstructured":"Hengge UR et al (2003) Oxymetholone for the treatment of HIV-wasting: a double-blind, randomized, placebo-controlled phase III trial in eugonadal men and women. HIV Clin Trials 4:150\u2013163","journal-title":"HIV Clin Trials"},{"key":"1214_CR54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archpsyc.57.2.141","volume":"57","author":"Rabkin","year":"2000","unstructured":"Rabkin JG, Wagner GJ, Rabkin R (2000) A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 57:141\u2013147, discussion 155\u2013146","journal-title":"Arch Gen Psychiatry"},{"key":"1214_CR55","doi-asserted-by":"crossref","first-page":"E1135","DOI":"10.1152\/ajpendo.90213.2008","volume":"294","author":"Knapp","year":"2008","unstructured":"Knapp PE et al (2008) Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. Am J Physiol Endocrinol Metab 294:E1135\u20131143","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1214_CR56","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/01.jcp.0000132442.35478.3c","volume":"24","author":"Rabkin","year":"2004","unstructured":"Rabkin JG, Wagner GJ, McElhiney MC et al (2004) Testosterone versus fluoxetine for depression and fatigue in HIV\/AIDS: a placebo-controlled trial. J Clin Psychopharmacol 24:379\u2013385","journal-title":"J Clin Psychopharmacol"},{"key":"1214_CR57","first-page":"315","volume":"Endocrinol","author":"Howell","year":"2001","unstructured":"Howell SJ et al (2001) Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf) 55:315\u2013324","journal-title":"Clin"},{"key":"1214_CR58","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/00002030-199612000-00010","volume":"10","author":"Berger","year":"1996","unstructured":"Berger JR et al (1996) Oxandrolone in AIDS-wasting myopathy. Aids 10:1657\u20131662","journal-title":"Aids"},{"key":"1214_CR59","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/00002030-199711000-00008","volume":"11","author":"Coodley","year":"1997","unstructured":"Coodley GO, Coodley MK (1997) A trial of testosterone therapy for HIV-associated weight loss. Aids 11:1347\u20131352","journal-title":"Aids"},{"key":"1214_CR60","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1210\/jc.83.9.3155","volume":"83","author":"Bhasin","year":"1998","unstructured":"Bhasin S et al (1998) Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 83:3155\u20133162","journal-title":"J Clin Endocrinol Metab"},{"key":"1214_CR61","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/archinte.164.8.897","volume":"164","author":"Dolan","year":"2004","unstructured":"Dolan S et al (2004) Effects of testosterone administration in human immunodeficiency virus-infected women with low weight: a randomized placebo-controlled study. Arch Intern Med 164:897\u2013904","journal-title":"Arch Intern Med"},{"key":"1214_CR62","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1210\/jc.2004-1677","volume":"90","author":"Choi","year":"2005","unstructured":"Choi HH et al (2005) Effects of testosterone replacement in human immunodeficiency virus-infected women with weight loss. J Clin Endocrinol Metab 90:1531\u20131541","journal-title":"J Clin Endocrinol Metab"},{"key":"1214_CR63","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1210\/jc.83.8.2717","volume":"83","author":"Miller","year":"1998","unstructured":"Miller K et al (1998) Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab 83:2717\u20132725","journal-title":"J Clin Endocrinol Metab"},{"key":"1214_CR64","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004714-199902000-00006","volume":"19","author":"Rabkin","year":"1999","unstructured":"Rabkin JG, Wagner GJ, Rabkin R (1999) Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism. J Clin Psychopharmacol 19:19\u201327","journal-title":"J Clin Psychopharmacol"},{"key":"1214_CR65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(99)00036-0","volume":"25","author":"Rabkin","year":"2000","unstructured":"Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R (2000) DHEA treatment for HIV + patients: effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology 25:53\u201368","journal-title":"Psychoneuroendocrinology"},{"key":"1214_CR66","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1200\/JCO.1989.7.5.590","volume":"7","author":"Tannock","year":"1989","unstructured":"Tannock I et al (1989) Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590\u2013597","journal-title":"J Clin Oncol"},{"key":"1214_CR67","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000026820","volume":"21","author":"Kneifel","year":"1998","unstructured":"Kneifel B et al (1998) Oral dexamethasone for the amelioration of the gemcitabine-induced side effects asthenia, edema, and flu-like symptoms: A pilot trial in 35 patients with various malignancies. Onkologie 21:229\u2013231","journal-title":"Onkologie"},{"key":"1214_CR68","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/oxfordjournals.annonc.a059358","volume":"6","author":"Amato","year":"1995","unstructured":"Amato R et al (1995) A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma. Ann Oncol 6:911\u2013914","journal-title":"Ann Oncol"},{"key":"1214_CR69","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0269216308101486","volume":"23","author":"Lundstrom","year":"2009","unstructured":"Lundstrom S, Furst CJ, Friedrichsen M, Strang P (2009) The existential impact of starting Kortikosteroid treatment as symptom control in advanced metastatic cancer. Palliat Med 23:165\u2013170","journal-title":"Palliat Med"},{"key":"1214_CR70","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/104990910101800510","volume":"18","author":"Rousseau","year":"2001","unstructured":"Rousseau P (2001) The palliative use of high-dose Kortikosteroids in three terminally ill patients with pain. Am J Hosp Palliat Care 18:343\u2013346","journal-title":"Am J Hosp Palliat Care"},{"key":"1214_CR71","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1191\/026921601673324846","volume":"15","author":"Hardy","year":"2001","unstructured":"Hardy JR et al (2001) A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med 15:3\u20138","journal-title":"Palliat Med"},{"key":"1214_CR72","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/02841860500401167","volume":"45","author":"Lundstrom","year":"2006","unstructured":"Lundstrom SH, Furst CJ (2006) The use of Kortikosteroids in Swedish palliative care. Acta Oncol 45:430\u2013437","journal-title":"Acta Oncol"},{"key":"1214_CR73","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1542\/peds.104.6.e73","volume":"104","author":"Fox-Wheeler","year":"1999","unstructured":"Fox-Wheeler S et al (1999) Evaluation of the effects of oxandrolone on malnourished HIV-positive pediatric patients. Pediatrics 104:e73","journal-title":"Pediatrics"},{"key":"1214_CR74","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00002030-199606001-00008","volume":"10","author":"Gold","year":"1996","unstructured":"Gold J et al (1996) Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. Aids 10:745\u2013752","journal-title":"Aids"},{"key":"1214_CR75","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0163-8343(98)00024-3","volume":"20","author":"Wagner","year":"1998","unstructured":"Wagner GJ, Rabkin JG, Rabkin R (1998) Testosterone as a treatment for fatigue in HIV + men. Gen Hosp Psychiatry 20:209\u2013213","journal-title":"Gen Hosp Psychiatry"},{"key":"1214_CR76","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0163-8343(94)00062-I","volume":"17","author":"Rabkin","year":"1995","unstructured":"Rabkin JG, Rabkin R, Wagner G (1995) Testosterone replacement therapy in HIV illness. Gen Hosp Psychiatry 17:37\u201342","journal-title":"Gen Hosp Psychiatry"},{"key":"1214_CR77","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1079\/BJN19960116","volume":"75","author":"Hengge","year":"1996","unstructured":"Hengge UR, Baumann M, Maleba R et al (1996) Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br J Nutr 75:129\u2013138","journal-title":"Br J Nutr"},{"key":"1214_CR78","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1258\/0956462981921026","volume":"9","author":"Wagner","year":"1998","unstructured":"Wagner GJ, Rabkin JG (1998) Testosterone therapy for clinical symptoms of hypogonadism in eugonadal men with AIDS. Int J STD AIDS 9:41\u201344","journal-title":"Int J STD AIDS"},{"key":"1214_CR79","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00007611-199308000-00003","volume":"86","author":"Berger","year":"1993","unstructured":"Berger JR, Pall L, Winfield D (1993) Effect of anabolic steroids on HIV-related wasting myopathy. South Med J 86:865\u2013866","journal-title":"South Med J"},{"key":"1214_CR80","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00018-011-0883-3","volume":"69","author":"Dubois","year":"2011","unstructured":"Dubois V, Laurent M, Boonen S et al (2011) Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions. Cell Mol Life Sci 69(10):1651\u20131667","journal-title":"Cell Mol Life Sci"},{"key":"1214_CR81","first-page":"394","volume":"94","author":"Sladek","year":"2006","unstructured":"Sladek R, Tieman J, Fazekas BS et al (2006) Development of a subject search filter to find information relevant to palliative care in the general medical literature. J Med Libr Assoc 94:394\u2013401","journal-title":"J Med Libr Assoc"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-012-1214-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00482-012-1214-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-012-1214-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T14:24:57Z","timestamp":1562163897000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00482-012-1214-9"}},"subtitle":["Eine systematische \u00dcbersichtsarbeit"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1007\/s00482-012-1214-9","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}